2017 version of the drug catalog: innovative drug competition to the market.


Release time:

2017-03-01

On February 21, the Ministry of Human Resources and Social Security issued the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition) (hereinafter referred to as the Drug Catalog). Chen Jinfu, director of the Medical Insurance Department of the Ministry of Human Resources and Social Security, said that the 2017 version of the drug catalog is the fourth time that the drug catalog has been adjusted since the establishment of my country's basic medical security system.

The drug catalog adjustment has many highlights:

First, 91 new varieties of children's drugs have been added. The number of drugs or dosage forms that are clearly applicable to children in the drug catalog has reached 540, further strengthening the protection of children's medication.

The second is to increase support for innovative drugs. The adjustment of the drug catalogue will focus on the new drugs listed after 2009, and further tilt the innovative drugs among them. From 2008 to the first half of 2016, the vast majority of innovative drugs and biological products approved in China were included in the scope of the 2017 version of the drug catalogue or the scope of negotiated drugs, and only a few varieties were not included because they did not fall within the scope of medical insurance payment (vaccines) or had low clinical recognition.

Three is to focus on the treatment of major diseases. Commonly used drugs for the treatment of major diseases such as cancer, severe mental illness, hemophilia, diabetes, and cardiovascular and cerebrovascular diseases have basically been included in the drug catalog or negotiated drug scope.

Four is to strongly support traditional Chinese medicine, ethnic medicine. On the basis of adhering to the principle of "equal emphasis on Chinese and Western medicine", we will increase support for traditional Chinese medicine and ethnic medicine. The proportion of western medicine and proprietary Chinese medicine in the 2017 edition of the drug catalogue reached 51% and 49%, basically the same. The relevant departments have specially organized experts in Tibetan medicine, Mongolian medicine and Victoria medicine to review Tibetan medicine, Mongolian medicine and Victoria medicine. This time, 41 new ethnic drugs were added, an increase of 90%, significantly higher than other drugs.

Five is to do a good job with the 2015 national negotiations on drugs. Tenofovir, icotinib and gefitinib were all included in the drug list by expert review.

Six is to strongly support the basic drug system. The vast majority of national essential drugs are included in the Class A part of the drug list, and the payment ratio is higher than that of Class B drugs.

In addition, considering that some drugs have high clinical value but are relatively expensive, according to the actual situation that the inclusion of the current price in the drug list may bring greater pressure to the medical insurance fund, experts have simultaneously reviewed and determined 45 drugs to be negotiated, and the next step will be Appropriately reduce the price through negotiation before being included in the drug list.

The relevant person in charge of the Social Insurance Management Center of the Ministry of Human Resources and Social Security said in an interview with reporters on February 24 that the 2017 version of the drug catalog fully reflects the spirit of handing competition to the market in the collection of innovative drugs and biological products. In recent years, China's drug innovation and research and development has made rapid progress, so that people can enjoy the medical achievements brought about by scientific and technological progress as soon as possible. The latest scientific and technological achievements can truly reflect their value in the competition only if they are tested for clinical efficacy.

The proportion of proprietary Chinese medicines in the 2017 edition of the drug catalogue has increased significantly, in line with the general trend of helping the development of Chinese medicine. However, in terms of the number of varieties, although the proportion of western medicine and Chinese patent medicine is 51% and 49% respectively, the number of drugs is still significantly higher than that of Chinese patent medicine due to the use of common names in western medicine.